Head-to-head evidence
LY3962681 vs UCB7853
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
LY3962681
Developed by Prevail Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2030 · NCT06565195 (registry estimate)
UCB7853
Developed by UCB
NCT04651153 · Phase 1 · completed
This was a randomized, quadruple-blind, placebo-controlled study, a sound design for an early safety trial that included both healthy volunteers and Parkinson's disease patients, but its only endpoints were safety-related, and results are not yet posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY3962681's landscape · UCB7853's landscape